Oremten (Emtricitabine, Tenofovir Disoproxil)

Emtricitabine, the active ingredient in Oremten, is a nucleoside reverse transcriptase inhibitor presented as a fixed‑dose combination for oral use. It treats HIV‑1 infection in adults and adolescents when used as part of combination antiretroviral therapy. GNH USA supplies Oremten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oremten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oremten combines two nucleos(t)ide reverse transcriptase inhibitors that act on the HIV replication cycle.

- HIV‑1 infection (adult & adolescent): improves viral suppression when used with other antiretrovirals. - Post‑exposure prophylaxis (PEP): contributes to preventing the establishment of HIV infection after potential exposure. - Pre‑exposure prophylaxis (PrEP) (high‑risk individual of the C  ​  ​  ​  ​  ​  ​  ​  …